Summary & Overview
HCPCS L8630: Metacarpophalangeal Joint Implant
HCPCS Level II code L8630 identifies a metacarpophalangeal (MCP) joint implant device used in surgical reconstruction or replacement of MCP joints. Nationally, device-side billing codes like L8630 matter for pricing transparency, device tracking, and proper facility and device reimbursement across payers. This publication examines how L8630 is categorized and billed and summarizes payer coverage patterns and benchmarks.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The report outlines what readers will learn about payer coverage approaches, common claim contexts, and clinical settings where the device is used. It highlights national considerations for device billing, coding accuracy, and administrative documentation associated with MCP joint implants.
Readers will find benchmarks and descriptive summaries of payer policies, an overview of clinical context for use of the device, and notes on typical service lines and sites of service for procedures using L8630. Where input data is incomplete, the publication notes that specific payer policy details or related code groupings are not available in the input.
Billing Code Overview
HCPCS Level II code L8630 represents a metacarpophalangeal joint implant device. This code describes an implanted prosthetic device used to replace or reconstruct the metacarpophalangeal (MCP) joint, typically to restore function and relieve pain caused by arthritis, trauma, or degenerative conditions.
-
Service type: Implantable joint prosthesis
-
Typical site of service: Hospital inpatient or outpatient surgery center, or ambulatory surgical center where hand and upper extremity orthopedic procedures are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old manual laborer or homemaker presenting with progressive pain, stiffness, and loss of motion at the metacarpophalangeal (MCP) joint of the index or middle finger. Conservative care including activity modification, splinting, nonsteroidal anti-inflammatory drugs, corticosteroid injections, and hand therapy have failed to provide durable relief. Imaging (plain radiographs, sometimes CT) demonstrates MCP joint arthrosis with joint space narrowing, osteophyte formation, and subchondral sclerosis. The surgical workflow includes preoperative evaluation and clearance, regional or general anesthesia, surgical exposure of the MCP joint, removal of arthritic joint surfaces, sizing and implantation of a L8630 metacarpophalangeal joint implant, intraoperative fluoroscopic confirmation of alignment and implant position, layered closure, and a period of immobilization followed by hand therapy for range of motion and strengthening. Typical sites of service are an ambulatory surgery center or hospital outpatient department; inpatient admission is uncommon unless there are medical comorbidities requiring observation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard billing | Used when no special circumstances apply and full global period services are billed |